The Trump administration on Thursday, February 5, 2026, officially launched TrumpRx.gov, a new government-hosted website designed to help Americans access discounted prescription medications. President Donald J. Trump announced the initiative, stating it would allow patients to buy drugs at reduced rates. The site debuted with offers for more than 40 medications, including popular weight-loss and diabetes treatments.^{[1][2][3][4][5][6]} ### How TrumpRx Connects Patients to Savings TrumpRx.gov acts as a facilitator, not a direct seller of drugs. The platform guides users to pharmaceutical companies' direct-to-consumer websites where they can complete purchases. It also provides coupons for use at pharmacies.^{[1][2][3][7][6]} This approach aims to streamline access to lower prices negotiated by the administration.^[4] The website primarily targets cash-paying patients, including those without insurance or individuals choosing to pay out-of-pocket instead of using their insurance.^[8][7][6] Importantly, any spending through TrumpRx will not count towards an individual's insurance deductible.^[7] Patients with insurance should check their co-pay first, as it might offer an even lower price.^[5][7][6] Among the initial medications listed on TrumpRx.gov are widely used drugs for weight loss and diabetes, such as Ozempic and Wegovy, and diabetes medication Zepbound.^{[1][3][9][5][6]} Patients can find significant price reductions. For example, monthly prices for Ozempic and injectable Wegovy could drop from $1,028 and $1,349, respectively, to an average of $350 and as low as $199.^[3] The Wegovy pill might see its price fall from $1,349 to as low as $149 per month.^[3][10] Zepbound's monthly cost could decrease from $1,088 to between $299 and $346.^[3][10] Pharmaceutical giant Pfizer also joined the platform, offering savings up to 85%, averaging 50%, on over 30 of its primary care and select specialty brands.^[8] Dr. Mehmet Oz, the administrator of the Centers for Medicare and Medicaid Services, urged consumers to use the new resource. "You should not be buying drugs anymore, going forward, without at least checking to see if those medications are available at these discounted prices," Dr. Oz said.^[5][11] ### Most-Favored-Nation Pricing Drives Discounts The launch of TrumpRx.gov is a key component of the Trump administration's broader "Most-Favored-Nation" (MFN) pricing initiative.^{[3][9][10][12][13][14][6]} This policy aims to ensure that Americans pay prices for prescription drugs that are comparable to the lowest prices paid by other developed nations.^{[3][10][12][14]} President Trump has repeatedly stated that Americans have historically paid disproportionately high prices for medications, effectively subsidizing lower costs for other countries.^[1][5][12] The administration formalized its push for MFN pricing through executive orders. On May 12, 2025, President Trump signed an Executive Order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients."^{[3][9][12][13]} This order directed federal agencies to take actions to align U.S. drug prices with those paid by similar nations.^[12][13] Following this, on July 31, 2025, President Trump sent letters to leading pharmaceutical manufacturers, outlining steps they needed to take to lower drug prices in the United States.^[3][9] Since September 30, 2025, the Trump administration has announced 16 deals with major pharmaceutical manufacturers.^[3] These agreements aim to bring drug prices in line with international rates, promising substantial relief for millions of Americans.^[3][9] The initial five manufacturers to reach MFN pricing deals and feature drugs on TrumpRx.gov include AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.^[3] ### Administration's Goals and Broader Context The launch of TrumpRx.gov reflects the administration's focus on addressing the high cost of healthcare and prescription drugs, which has become a significant financial concern for many Americans.^[1][2][7] Affordability of essential goods, including medications, emerged as a political vulnerability for the administration leading into the November midterm elections.^[1][2] President Trump emphasized that his administration's pressure on pharmaceutical companies made the lower prices possible.^[1] Joe Gebbia, an Airbnb founder and the administration's Chief Design Officer, contributed to the website's design, with plans to add more drugs to TrumpRx over time.^[5] While TrumpRx is a direct administration initiative, it also interacts with other drug pricing efforts. The administration has also engaged in Medicare drug price negotiations, building on provisions from the Inflation Reduction Act of 2022.^[15][11][16] These separate negotiation efforts for Medicare Part D drugs are projected to save Medicare billions of dollars and reduce out-of-pocket costs for beneficiaries.^[15] The TrumpRx platform represents a distinct effort to provide immediate, direct-to-consumer discounts, particularly benefiting those who pay cash for their medications. The administration aims to continue expanding the list of available drugs and the scope of savings for American patients.

AI Insights Hub